Join Us in San Francisco, October 27-28! REDWOOD CITY, Calif., June 9, 2025 /PRNewswire/ -- The Tianqiao and Chrissy Chen…
Facilities and care team tailored for patients with complex medical needs Specialized protocol includes optimized dosing and therapeutic support for…
Exhibits complex neurological processes—including memory, learning, and cognition—and predicts human outcomes in preclinical drug development NEW ORLEANS, June 9, 2025…
Data show SPR301 lowered α-synuclein, a hallmark of Parkinson’s disease, in cellular models, indicating potential for efficacy at doses with…
Top three teams recognized for ideas to create sustainable electric mobility, tumor diagnostics accuracy and remote neurological monitoring BENGALURU, India,…
Vancouver, British Columbia--(Newsfile Corp. - June 5, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF)…
Annamycin delivering better performance 7th line than would be expected even in 2nd line for monotherapy Responders (Stable Disease or…
Phase 11 First-In-Human study designed to assess safety, tolerability, right dose for Phase 2 and early signs of efficacy of…
Funding expected to support operations into Q1 2026. Anticipated AMPLIFY-7P Phase 2 interim analysis expected in Q3 2025. BOSTON, June…
BrainsWay is actively evaluating similar investments in other leading U.S. mental health providers to raise awareness and expand access to…